Skip to content
Homepage
Author:
Vesalio
Posted Date:
July 22, 2026
Vesalio Announces Late-Breaking Clinical Trial Presentation of the enVast NATURE Study at the ESC Congress 2026
Vesalio
July 22, 2026
Vesalio Appoints Greg Cook as Chief Commercial Officer
Vesalio
July 14, 2026
Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters
Vesalio
February 12, 2026
